COMMUNIQUÉS West-GlobeNewswire

Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting
12/03/2018
Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting - Clinical and real-world insights on recombinant human parathyroid hormone ( 1-84) (rhPTH[1-84]) and [...]
Bavarian Nordic Awards Restricted Stock Units to Executive Management
12/03/2018
COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management. The Board of Directors of [...]
Bavarian Nordic Announces Annual Report 2017
12/03/2018
COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2017. Below is a summary of business progress, financial performance for the year and financial [...]
Novartis announces changes to the Executive Committee to support strategic priorities
12/03/2018
Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger named Chief Ethics, Risk and [...]
Novartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques
12/03/2018
Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN Shannon Klinger est [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/03/2018
REGULATED INFORMATION GHENT, Belgium, 12 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
IBA SA : IBA signs three new Proteus®ONE contracts with Proton Partners International
12/03/2018
IBA signs three new Proteus ® ONE contracts with Proton Partners International IBA to install three additional Proteus ® ONE compact proton therapy solutions in the UK Louvain-La-Neuve, Belgium, 12 March 2018 - IBA (Ion [...]
IBA SA : IBA signe trois nouveaux contrats Proteus®ONE avec Proton Partners International
12/03/2018
IBA signe trois nouveaux contrats Proteus ® ONE avec Proton Partners International IBA va installer trois solutions compactes de protonthérapie Proteus ® ONE supplémentaires au Royaume-Uni Louvain-la-Neuve, Belgique, 12 [...]
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
12/03/2018
Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors SAN DIEGO, March 11, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (Arcturus or the Company) (NASDAQ: ARCT ), an RNA [...]
Immutep Raises A$6.85m Through Institutional Placement
12/03/2018
A$6.85m raised through share institutional placement to drive immuno-oncology development programs Placement of new ordinary shares to leading Australian healthcare institutional investors Platinum Asset Management and [...]
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement With MSD
12/03/2018
SYDNEY, Australia, March 11, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ: IMMP ) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement [...]
Clinical Trials Show Strong Long-Term Performance with the Medtronic CoreValve TAVR System
10/03/2018
Presented at ACC.18, Five-Year Follow-up from the CoreValve Extreme Risk and NOTION Studies Show Sustained Valve Function and Durability Over Time DUBLIN and ORLANDO - March 10, 2018 - Medtronic plc (NYSE: MDT) today [...]
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
10/03/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Regeneron announce plans to make Praluent ® more accessible and affordable for patients with the greatest health risk and unmet need Precision medicine [...]
Sanofi et Regeneron annoncent leurs plans pour rendre Praluent® plus facilement accessible et économiquement abordable aux patients à risque élevé présentant d'importants besoins non satisfaits
10/03/2018
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi et Regeneron annoncent leurs plans pour rendre Praluent ® plus facilement accessible et économiquement abordable aux patients à risque élevé [...]
Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
10/03/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Praluent ® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate ODYSSEY OUTCOMES trial [...]
Sanofi : Praluent® (alirocumab) a significativement réduit le risque d'événements cardiovasculaires chez des patients à risque élevé, et a été associé à une réduction du taux de mortalité
10/03/2018
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Praluent ® (alirocumab) a significativement réduit le risque d'événements cardiovasculaires chez des patients à risque élevé, et a été associé à une [...]
SuperSonic Imagine Vows To Vigorously Defend Against Intellectual Property Lawsuit
09/03/2018
AIX-EN-PROVENCE, France, March 09, 2018 (GLOBE NEWSWIRE) -- SuperSonic Imagine (Euronext:SSI) (FR0010526814), a company specialised in medical imaging using ultrasound, said today that it strongly denies allegations [...]
BioStem Technologies Inc. Enter into Agreement with Barbara Krutchkoff, PhD. To Guide Scientific Affairs
09/03/2018
Pompano Beach, FL, March 09, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in [...]
Profound Medical to Release Fourth Quarter and Full Year 2017 Financial Results on March 26, 2018 – Conference Call to Follow
09/03/2018
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to offer a therapeutic platform that provides the precision of real-time MR [...]

Pages